Hadassah

Hadassah Research Leads to Patent for Diabetes-Related Oral Delivery Technology

Thursday, Jan 22 2015

Oramed Pharmaceuticals Inc., focused on the development of oral drug delivery systems including an oral insulin pill based on Hadassah Medical Organization research, has received a patent from the Israel Patent Office for its invention, “Methods and Compositions for Oral Administrations of Exenatide.”

Eexenatide, a glucagon-like peptide-1 (GLP-1) analog, is a hormone which induces insulin release at increased glucose levels and causes a feeling of satiety, resulting in reduced food intake and weight loss. Currently, it is only marketed in injectable form. Oramed’s oral GLP-1 capsule, according to Oramed, could significantly increase compliance and become a valuable tool in the treatment of diabetes.

Oramed was founded in 2006 by Dr. Miriam Kidron, a senior researcher in the Diabetes Unit at Hadassah, who continues to serve as the company’s chief scientist. A pharmacologist and biochemist, Dr. Kidron earned her PhD in biochemistry from the Hadassah-Hebrew University and earned the Bern Schlanger Award for her work in diabetes research. Formerly a visiting professor at the Medical School at the University of Toronto, she is a member of the American, European, and Israeli diabetes associations.

Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Hadassah. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes, under an Investigational New Drug application with the United States Food and Drug Administration.

Read more

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›
alt_text

Thursday, Nov 17 2016

A Birthday Party in Hadassah’s PICU: Helping a Four-Year-Old Recover

Yehoshua "Shuki" Pepper was crossing a Jerusalem street with an older sibling when a car ran him over. He was rushed to Hadassah Hospital Ein Kerem's Pediatric Intensive Care Unit in fair condition, but he wasn't speaking and subsequent MRIs of his head injury were worrisome.

READ MORE ›
alt_text

Thursday, Nov 17 2016

Ethiopian Pre-Nursing Students: On the Way to Fulfilling a Dream

“I know that some people are fine with looking at a screen all day, but I know I need the human touch--to work with people. I want to be a nurse, " relates Sarah Talala, one of the 18 students of Ethiopian background who were given the opportunity to take a course which enabled them to advance to pre-academic studies at the Hebrew University and then on to nursing school at the Hadassah-Hebrew University Henrietta Szold School of Nursing.

READ MORE ›
alt_text

Monday, Nov 14 2016

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More